Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shorter h. pylori treatment put to the test: 10 days vs. 14 days

NCT ID NCT07720037

Disease control Sponsor: Shandong University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial tests whether a 10-day course of high-dose vonoprazan plus amoxicillin can clear Helicobacter pylori infection as effectively as the standard 14-day regimen. Adults aged 18 to 70 with a current H. pylori infection and no prior treatment are randomly assigned to one of two groups. The main goal is to compare how well each treatment eradicates the bacteria, with follow-up testing after treatment ends.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
vonoprazan and amoxicillin
What this could lead to
If the shorter, higher-dose regimen works as well as the standard 14-day course, it could simplify treatment and reduce the time patients need to take medication for H. pylori.
What could go wrong
This is a phase 4 trial with 232 participants, so results may not apply to everyone. The shorter regimen might cause more side effects or fail to clear the bacteria in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 232 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18 to 70 years, no restriction on gender 2. Current Helicobacter pylori infection (positive result of either ¹³C or ¹⁴C urea breath test) 3. No prior history of Helicobacter pylori eradication therapy Exclusion Criteria: 1. Severe underlying diseases, including hepatic insufficiency, renal insufficiency, malignant tumors, etc. 2. Active gastrointestinal bleeding 3. History of upper gastrointestinal surgery 4. History of allergy to study medications 5. Use of bismuth agents or antibiotics within 4 weeks prior to enrollment; use of acid-suppressive agents within 2 weeks prior to enrollment 6. Pregnant or breastfeeding women, and subjects who refuse to take contraceptive measures during the trial 7. Behaviors that may increase disease risks, such as chronic alcohol abuse and drug addiction 8. Subjects who are unable or unwilling to sign the informed consent form

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amoxicillin are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Amoxicillin Helicobacter infection Vonoprazan

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.